vialroom

#bloodwork 2025-01-30

Thursday42 messages9 participantstimes are UTC
Highlights from this day
  • swirl_not_shake — then measure both and stop arguing with me about it 22:51
  • peak_split — pulling it out so nobody has to scroll for it again 22:58
  • peak_split — and for the bigger question of whether any of this matters, SELECT is the one that moved the needle 23:00
  • swirl_not_shake — the trial population is the trial population. people forget that constantly 23:05

the most useful thing i did was get a full panel before i started. everything since has been comparable

alt and ast coming down as you lose liver fat is common and is a good sign

🙏4

baseline, three months, then twice a year is what i settled on

anyone have before and after numbers they are willing to post

📉1👀7

apob is the better marker and it is harder to get. i track both because i can only get one reliably

[edited]

too early for a1c

BV

my LDL-C is 2.6 and my doctor is happy, so why do you all keep going on about apoB

PS

because LDL-C is a mass measurement and apoB is a particle count

you can carry the same cholesterol mass in a few large particles or in a lot of small ones. the second is worse

SN

and in exactly our population — high triglycerides, low HDL — the two disagree most

PS

the four cases

PatternLDL-CapoBWhat it means
concordantnormalnormalno argument to have
discordant, high trigslooks finehighmore particles, each carrying less cholesterol
discordant, other waylooks highnormalfewer, larger particles
during active weight lossunstablesteadierwhy people prefer apoB mid-cut
📌10
PS

the genetic and epidemiological case is strong. a trial that randomised people to apoB-guided versus LDL-guided treatment is not something we have

PS

inference from several directions. the same is true of most of lipid practice

PS

this is a genuine disagreement and it does not resolve in here. it has not resolved in the literature either

PS

and for the bigger question of whether any of this matters, SELECT is the one that moved the needle

Cited study
Semaglutide and Cardiovascular Outcomes in Overweight or Obesity (SELECT)
New England Journal of Medicine · 2023
semaglutide 2.4 mg reduced major adverse cardiovascular events versus placebo in people with established cardiovascular disease and without diabetes
PS

in that population, with established disease, yes. it does not follow that it does the same for a 30 year old with none

SN

the trial population is the trial population. people forget that constantly

11